Targeted Oncology

Target Oncol

1776-2596

1776-260X

Therapeutic Area

Hematology, Oncology, Pharmacology, Pharmacy, Public Health, Toxicology

Caregivers, Healthcare Executives, Hematologists, Hospitalists, Internists, Oncologists, Patients, Pharmacists, Pharmacologists, Physicians - Medicine, Public Health Professionals, Toxicologists

Targeted Oncology addresses physicians and scientists committed to oncology and cancer research by providing a programme of articles on molecularly targeted pharmacotherapy in oncology. "Targeted Oncology is a pragmatic tool for all physicians and scientists committed to oncology and cancer research. Recently, a better understanding of the genetics and biology of cancer have provided important clues to the pathology of the disease and to new therapeutic strategies. Innovative treatments, including small molecule inhibitors and biologicals targeting oncogenic pathways and immune checkpoints have emerged and are currently revolutionizing the way we treat cancer patients. Despite these breakthroughs, significant work remains in understanding these new compounds and identifying markers of treatment success. Targeted Oncology focuses on Original Research Articles on both pre-clinical and clinical aspects of molecularly targeted agents, and on comprehensive narrative Review Articles discussing clinically established as well as emerging agents and pathways. The journal also publishes Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement, and Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.

No associations affiliated with this journal

Adis, part of Springer Nature

Impact Factor JCR Categories/Rank Electronic Circulation Submission to Acceptance Acceptance to Online Publication Acceptance to Print Publication Rejection Rate Frequency Journal Contact Author Submission Guidelines